Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Guttman, Emma [2 ]
Hussain, Iftikhar [3 ]
Chen, Zhen [4 ]
Mina-Osorio, Paola [4 ]
Rossi, Ana Beatris [5 ]
Bansal, Ashish [4 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Vital Prospects Clin Res Inst PC, Tulsa, OK USA
[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[5] Sanofi Genzyme, Cambridge, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15108
引用
收藏
页码：AB141 / AB141
页数：1
相关论文
共 50 条
  • [41] Long-Term Efficacy and Safety with Lanreotide Autogel/ Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
    Phan, A. T.
    Pavel, M.
    Caplin, M.
    Wolin, E. M.
    Mirakhur, B.
    Massien, C.
    Liyanage, N.
    Lowenthal, Pittman S.
    Ruszniewski, P.
    [J]. NEUROENDOCRINOLOGY, 2017, 105 : 207 - 207
  • [42] Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial
    Beck, Lisa A.
    Deleuran, Mette
    Hong, H. Chih-Ho
    Adam, David N.
    Hussain, Iftikhar
    Zhang, Haixin
    Shabbir, Arsalan
    Rodriguez Marco, Ainara
    Levit, Noah A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB206 - AB206
  • [43] Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial
    Cork, Michael J.
    Beck, Lisa A.
    Deleuran, Mette
    Hong, H. Chih-ho
    Adam, David N.
    Hussain, Iftikhar
    Zhang, Haixin
    Shabbir, Arsalan
    Rodriguez Marco, Ainara
    Levit, Noah A.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1014 - 1014
  • [44] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Soong, W.
    Goooderham, M.
    Bissonnette, R.
    Xiao, J.
    Khokhar, F. A.
    Marco, A. R.
    Levit, N. A.
    Shabbir, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
  • [45] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [46] DUPILUMAB PROVIDES LONG-TERM EFFICACY FOR UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Deleuran, Mette
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Lockshin, Benjamin
    Galus, Ryszard
    Lynde, Charles
    Xiao, Jing
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 34
  • [47] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [48] Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Blauvelt, A.
    Lockshin, B.
    Galus, R.
    Lynde, C.
    Xiao, J.
    Levit, N. A.
    Marco, A. R.
    Shabbir, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
  • [49] Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Eichenfield, L.
    Chen, Z.
    Sierka, D.
    Vakil, J.
    Khokhar, F. A.
    Cyr, S. L.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E121 - E121
  • [50] Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
    Michael J. Cork
    Diamant Thaçi
    Lawrence F. Eichenfield
    Peter D. Arkwright
    Zhen Chen
    Ryan B. Thomas
    Matthew P. Kosloski
    Ariane Dubost-Brama
    Randy Prescilla
    Ashish Bansal
    Noah A. Levit
    [J]. Dermatology and Therapy, 2023, 13 : 2697 - 2719
12345